Laboratory revenue cycle management encompasses every operational process connecting clinical laboratory services to collected Medicare reimbursement – and in August 2026, it has become the most actionable lever available to laboratory executives preparing for a confirmed payment shift. The Consolidated Appropriations Act, 2026, signed February 3, 2026, delayed all PAMA-related Clinical Laboratory Fee Schedule (CLFS) rate reductions through December 31, 2026 – the seventh Congressional intervention since PAMA was enacted [1]. But the reprieve is temporary.

You’re leaving $25-$40 per visit on the table every time a legitimate 99214 gets downcoded to 99213. Not because someone...
read more
Imagine this medical billing and credentialing scenario: You’ve hired a new physician. Their start date is set. Patients...
read more
You’re wrapping up a 10-hour shift. One more note to finish, one last patient to call – and then someone from billing wa...
read more
The healthcare revenue cycle is undergoing significant transformation, driven by evolving regulations, shifting payer po...
read more
The medical billing outsourcing market is experiencing unprecedented growth, with the global market size projected to re...
read more
In the high-stakes world of healthcare finance, where razor-thin margins and rising regulatory scrutiny are the norm, me...
read more
Pediatric medicine supports some of the most vulnerable members of society. This makes shortages in the space even more ...
read more